IP Library › Patent Application 16228682
Patent Application
App. No. 16/228,682

PHARMACEUTICAL FORMULATIONS OF A BRUTONS TYROSINE KINASE INHIBITOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/228,682
Abstract

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claims (3)

1 . A high-load solid tablet formulation comprising ibrutinib and one or more pharmaceutically acceptable excipients, wherein ibrutinib is a compound with the structure of Compound 1,

and wherein the high-load solid tablet formulation comprises at least 50% w/w of ibrutinib.

2 - 54 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: CHONG, CHING W.; KUEHL, ROBERT; TAN, HEOW; ATLURI, HARISHA
To: PHARMACYCLICS LLC
Reel/Frame 048157/0283 →